Premium
Intravenous Gamma‐Globulin (Sandoglobulin®) Therapy in the Management of Four Patients with Immune Thrombocytopenic Purpura
Author(s) -
Blanchette Victor S.
Publication year - 1985
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.1985.tb01141.x
Subject(s) - gamma globulin , thrombocytopenic purpura , medicine , purpura (gastropod) , immunology , immune system , antibody , biology , ecology
We have used intravenous polyvalent intact gamma‐globulin concentrate (Sandoglobulin®‐immune globulin IV) in the management of 2 adults and 2 children with refractory immune thrombocytopenic purpura (ITP). Excellent responses were obtained in 2 children with chronic ITP as compared to no response in 2 adults with long‐standing, severe ITP. The 2 adults who failed intravenous Sandoglobulin therapy had prolonged reticuloen‐dothelial system (RES) clearance of autologous antibody‐coated red blood cells before initiation of therapy as compared to normal RES clearance rates in the 2 children who responded to therapy. Blockade of the RES is one mechanism by which intravenous Sandoglobulin therapy may reverse thrombocytopenia in ITP — our observations suggest that patients who have impaired RES function before starting intravenous Sandoglobulin therapy may fail to respond to treatment. Continued studies are required to confirm these observations.